Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening

This publication has 23 references indexed in Scilit:

• A new large-animal model for research of graft vascular disease
  Transplantation Proceedings, 1998
• THERAPEUTIC BLOOD LEVELS OF SIROLIMUS (RAPAMYCIN) IN THE ALLOGRAFTED RAT
  Transplantation, 1996
• Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide
  Current Opinion in Immunology, 1996
• TREATMENT WITH RAPAMYCIN AND MYCOPHENOLIC ACID REDUCES ARTERIAL INTIMAL THICKENING PRODUCED BY MECHANICAL INJURY AND ALLOWS ENDOTHELIAL REPLACEMENT
  Transplantation, 1995
• EFFECTS OF RAPAMYCIN ON GROWTH FACTOR-STIMULATED VASCULAR SMOOTH MUSCLE CELL DNA SYNTHESIS INHIBITION OF BASIC FIBROBLAST GROWTH FACTOR AND PLATELET-DERIVED GROWTH FACTOR ACTION AND ANTAGONISM OF RAPAMYCIN BY FK506
  Transplantation, 1995
• Prolongation Of Renal Allograft Survival In A Large Animal Model By Oral Rapamycin Monotherapy
  Transplantation, 1995
• RAPAMYCIN INHIBITS ARTERIAL INTIMAL THICKENING CAUSED BY BOTH ALLOIMMUNE AND MECHANICAL INJURY
  Transplantation, 1993
• THE RELATIONSHIP OF BLOOD CONCENTRATIONS OF RAPAMYCIN AND CYCLOSPORINE TO SUPPRESSION OF ALLOGRAFT REJECTION IN A RABBIT HETEROTOPIC HEART TRANSPLANT MODEL1
  Transplantation, 1993
• The Porcine Model for the Understanding of Thrombogenesis and Atherogenesis
  Mayo Clinic Proceedings, 1991
• RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING
  The Lancet, 1989